Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innogenetics launches Easdaq flotation at $11 a share

This article was originally published in Clinica

Executive Summary

Innogenetics, the Belgian manufacturer and developer of diagnostic and woundcare products, has launched its initial public offering last week, writes Brigitte Ascher. The prospectus assumes a price of $11 a share which would value the company at more than $220 million. With trading set to start on or before November 26th, Innogenetics will become one of the first companies quoted on the Easdaq, the new Brussels-based stock exchange modelled on the US Nasdaq. Shares will be quoted in US dollars.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel